吡格列酮辅助认知行为疗法预防可卡因复吸
The purpose of this study is to see how well pioglitazone, when used with cognitive behavioral therapy, works at helping people who have recently stopped using cocaine to continue to not use cocaine.
研究概览
详细说明
Over one million American adults suffer from cocaine use disorder (CUD) with recent trends showing an increase in cocaine-related deaths since 2010. For the chronic cocaine user, significant changes in brain function and structure set the stage for relapse that, unfortunately, continues to be the most common outcome following treatment. For substance use disorders, cognitive-behavioral therapy (CBT) is arguably the most empirically supported and widely used relapse prevention approach. Considered to be a cognitive control therapy, CBT aims to improve 'top-down' executive control functions that are impaired in CUD and strongly connected to relapse. Converging evidence suggests that CBT promotes meaningful changes in brain regions associated with cognitive control. Still, many patients with cognitive impairments show suboptimal response to CBT, bolstering the call for research aimed at improving effects with integrative treatments.
The goal of this project is to enhance the relapse-prevention effects of CBT with adjunctive use of pioglitazone (PIO), a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist. Unlike traditional medications that target classic neurotransmitter systems, PIO's activation of the PPAR pathway confers broad spectrum anti-inflammatory and neuroprotective effects against insult to brain white matter (WM). The functional significance of WM in CUD has been well established by evidence showing that: (1) chronic cocaine exposure alters WM structural integrity; (2) WM alterations compromise cognitive function in CUD; and (2) better WM integrity predicts better CUD treatment outcome. In a recent proof of concept trial it was found that PIO significantly improved brain WM integrity in a small sample of non-abstinent patients with CUD. Treatment with PIO was well-tolerated and associated with reduced cocaine craving relative to placebo. Collectively, these findings raise the exciting possibility that PIO may augment responding to CBT via improved neural structure and cognitive function.
A randomized double-blind clinical trial will be utilized to evaluate the efficacy of CBT with adjunctive PIO in recently abstinent patients during the early phase of recovery when craving is prominent, relapse risk is high, and intact cognitive control is required to actively maintain abstinence. Upon completion of a 5-day inpatient detoxification, 60 adults with CUD will complete titration to full dose of randomized medication, either PIO (45mg daily) or placebo, and begin 12 weeks of outpatient CBT treatment while continuing to receive study medication. Specific aims will examine the effects of PIO on targeted mechanisms of change (WM integrity, cognitive function, cocaine craving) and demonstrate evidence linking clinical efficacy (abstinence, functional health) with mechanism engagement. Expected results will establish PIO as an adjunctive treatment that can be integrated with CBT to reduce relapse risk following detoxification, thereby meeting NIDA's strategic priority of evaluating the use of medications to improve the efficacy of behavioral interventions (PA-18-055).
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Texas
-
Houston、Texas、美国、77054
- UTHealth Center for Neurobehavioral Research on Addiction
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 18 to 65 years old
- meet DSM 5 diagnostic criteria for cocaine use disorder
- report recent cocaine use, verified by at least one positive urine drug screen for the cocaine metabolite, benzoylecgonine, during intake
- be judged by the medical staff to be psychiatrically stable and physically healthy
- for females, be using an effective form of birth control (e.g., barrier, IUD, or sterilization) and not be pregnant as determined by a serum pregnancy test at screening and negative urine pregnancy test at intake prior to first dose of investigational drug (test will be repeated weekly to ensure that female patients do not continue in the study if pregnant) or lactating
- be willing to be admitted to a 5-day inpatient detoxification program at The Right Step Houston
- be able to understand the consent form and provide written informed consent
- be able to provide the names of at least 2 persons who can consistently locate their whereabouts
Exclusion Criteria:
- have an acute medical or psychiatric disorder that would, in the judgment of the study physician, make participation difficult or unsafe
- have suicidal or homicidal ideation that requires immediate attention
- have another current (≥ moderate) substance use disorder aside from alcohol, nicotine, or marijuana
- have a medical condition contraindicating PIO pharmacotherapy (e.g., drug- or insulin-dependent diabetes, congestive heart failure, edema, clinical significant liver disease, hypoglycemia, history of bladder cancer) or be taking medications that would adversely interact with PIO (e.g., CYP2C8 inhibitors or inducers, antihyperglycemic medications)
- be concurrently enrolled in other addiction treatment services aside from smoking cessation
- if female, be currently pregnant, breastfeeding, or planning on conception
- have conditions of probation or parole requiring reports of drug use to officers of the court
- be unable to read, write, or speak English
- be homeless (live on the street)
- have medical contraindications to MRI/DTI scans (e.g., history of pacemaker, metal implants, or welding/metal work without protective eyewear)
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器：CBT + pioglitazone
Cognitive Behavioral Therapy will be administered twice weekly during weeks 1-4 and once weekly during weeks 5-12 and augmented with a pioglitazone (45 mg) capsule every day during weeks 1-12. |
All participants will receive evidence-based individual Cognitive Behavioral Therapy (CBT) shown to be an effective intervention for maintaining abstinence following detoxification. Trained masters-level licensed professional counselors will deliver CBT.
其他名称：
Pioglitazone capsules will start at 30 mg (Detox days 3 and 4) and increase to fixed dose of 45 mg for study weeks 1-12 and will also contain riboflavin.
其他名称：
|
|
安慰剂比较：CBT + placebo
Cognitive Behavioral Therapy will be administered twice weekly during weeks 1-4 and once weekly during weeks 5-12 and augmented with a placebo capsule every day during weeks 1-12. |
All participants will receive evidence-based individual Cognitive Behavioral Therapy (CBT) shown to be an effective intervention for maintaining abstinence following detoxification. Trained masters-level licensed professional counselors will deliver CBT.
其他名称：
Placebo capsules will be filled with corn starch and riboflavin.
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in white matter integrity as assessed by change in fractional anisotropy value measured by diffusion tensor imaging
大体时间：Week 0 and Week 12
|
Anisotropy values range from 0 to 1, where a higher value indicates greater white matter integrity. |
Week 0 and Week 12
|
|
Change in white matter integrity as assessed by change in radial diffusivity value measured by diffusion tensor imaging
大体时间：Week 0 and Week 12
|
Radial diffusivity (RD) values are not bound by specified upper and lower ranges, as the metric is a derivation of two diffusion eigenvalues = ([lambda2 / lambda3] / 2). Higher RD values are indicative of decreased white matter integrity as related to myelin integrity; conversely lower RD scores indicate better white matter integrity. |
Week 0 and Week 12
|
|
Change in working memory as assessed by the NIH Toolbox Cognition Battery List Sorting Task
大体时间：Week 0
|
The List Sorting Task has an age-adjusted scale score that ranges from 0 to 100, with a higher score indicating better performance. |
Week 0
|
|
Change in working memory as assessed by the NIH Toolbox Cognition Battery List Sorting Task
大体时间：Week 4
|
The List Sorting Task has an age-adjusted scale score that ranges from 0 to 100, with a higher score indicating better performance. |
Week 4
|
|
Change in working memory as assessed by the NIH Toolbox Cognition Battery List Sorting Task
大体时间：Week 12
|
The List Sorting Task has an age-adjusted scale score that ranges from 0 to 100, with a higher score indicating better performance. |
Week 12
|
|
Change in attention/impulsivity as assessed by the NIH Toolbox Cognition Battery Flanker Test
大体时间：Week 0
|
The Flanker Test has an age-adjusted scale score that ranges from 0 to 100, with a higher score indicating better performance. |
Week 0
|
|
Change in attention/impulsivity as assessed by the NIH Toolbox Cognition Battery Flanker Test
大体时间：Week 4
|
The Flanker Test has an age-adjusted scale score that ranges from 0 to 100, with a higher score indicating better performance. |
Week 4
|
|
Change in attention/impulsivity as assessed by the NIH Toolbox Cognition Battery Flanker Test
大体时间：Week 12
|
The Flanker Test has an age-adjusted scale score that ranges from 0 to 100, with a higher score indicating better performance. |
Week 12
|
|
Change in cognitive function as assessed by the NIH Toolbox Cognition Battery Fluid Cognition Composite score
大体时间：Week 0
|
The Fluid Cognition Composite score is the normed standardized score ranging from 0 to 145, with a higher score indicating better performance. |
Week 0
|
|
Change in cognitive function as assessed by the NIH Toolbox Cognition Battery Fluid Cognition Composite score
大体时间：Week 4
|
The Fluid Cognition Composite score is the normed standardized score ranging from 0 to 145, with a higher score indicating better performance. |
Week 4
|
|
Change in cognitive function as assessed by the NIH Toolbox Cognition Battery Fluid Cognition Composite score
大体时间：Week 12
|
The Fluid Cognition Composite score is the normed standardized score ranging from 0 to 145, with a higher score indicating better performance. |
Week 12
|
|
Number of participants who don't relapse as assessed by continuous cocaine-negative urine drug screens in the final three weeks of treatment
大体时间：From Week 10 to Week 12
|
For a cocaine-negative urine drug screen result, benzoylecgonine levels must be under 150 ng/mL. |
From Week 10 to Week 12
|
|
Self-reported craving for cocaine as assessed by average Brief Substance Craving Scale score across 12 weeks of treatment
大体时间：From Week 1 to Week 12
|
The Brief Substance Craving Scale (BSCS) score ranges from 0 to 4, with a higher score indicating greater craving. Participants will be assessed by BSCS once per week for 12 weeks, and the average BSCS score over the 12 weeks will be reported. |
From Week 1 to Week 12
|
|
Self-reported craving for cocaine as assessed by average Visual Analogue Scale score across 12 weeks of treatment
大体时间：From Week 1 to Week 12
|
The Visual Analogue Scale (VAS) score ranges from 0 to 100, with a higher score indicating greater craving. Participants will be assessed by VAS once per week for 12 weeks, and the average VAS score over the 12 weeks will be reported. |
From Week 1 to Week 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Total percentage of days abstinent during treatment as assessed by self-reported non-use days confirmed by cocaine-negative urine drug screen results
大体时间：From Week 1 to Week 12
|
For a cocaine-negative urine drug screen result, benzoylecgonine levels must be under 150 ng/mL. |
From Week 1 to Week 12
|
|
Total percentage of cocaine-negative urine drug screens during treatment as assessed by number of cocaine-negative samples out of total number of urine samples provided
大体时间：From Week 1 to Week 12
|
For a cocaine-negative urine drug screen result, benzoylecgonine levels must be under 150 ng/mL. |
From Week 1 to Week 12
|
|
Functional health status as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) global health summary score
大体时间：Week 0
|
The PROMIS global health summary score is a T-score derived from the global physical health (GPH) and global mental health (GMH) items and ranges from 40 to 60, with a greater T-score indicating better functional health status. |
Week 0
|
|
Functional health status as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) global health summary score
大体时间：Week 4
|
The PROMIS global health summary score is a T-score derived from the global physical health (GPH) and global mental health (GMH) items and ranges from 40 to 60, with a greater T-score indicating better functional health status. |
Week 4
|
|
Functional health status as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) global health summary score
大体时间：Week 12
|
The PROMIS global health summary score is a T-score derived from the global physical health (GPH) and global mental health (GMH) items and ranges from 40 to 60, with a greater T-score indicating better functional health status. |
Week 12
|
合作者和调查者
调查人员
- 首席研究员：Joy M Schmitz, PhD、UT Houston
- 首席研究员：Scott D Lane, PhD、UT Houston
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- HSC-MS-19-0718
- R01DA048026 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.